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Abstract: Millions of patients worldwide suffer from gastrointestinal (GI) motility disorders such as 
gastroparesis. These disorders typically include debilitating symptoms, such as chronic nausea and 
vomiting. As no cures are currently available, clinical care is limited to symptom management, 
while the underlying causes of impaired GI motility remain unaddressed. The efficient movement 
of contents through the GI tract is facilitated by peristalsis. These rhythmic slow waves of GI muscle 
contraction are mediated by several cell types, including smooth muscle cells, enteric neurons, 
telocytes, and specialised gut pacemaker cells called interstitial cells of Cajal (ICC). As ICC 
dysfunction or loss has been implicated in several GI motility disorders, ICC represent a potentially 
valuable therapeutic target. Due to their availability, murine ICC have been extensively studied at 
the molecular level using both normal and diseased GI tissue. In contrast, relatively little is known 
about the biology of human ICC or their involvement in GI disease pathogenesis. Here, we 
demonstrate human gastric tissue as a source of primary human cells with ICC phenotype. Further 
characterisation of these cells will provide new insights into human GI biology, with the potential 
for developing novel therapies to address the fundamental causes of GI dysmotility. 
Keywords: gastrointestinal motility; peristalsis; interstitial cells of Cajal; ICC; molecular 
characterisation; bioinformatics; mouse; human; pluripotent stem cells. 
 
1. Introduction 
Gastrointestinal (GI) motility disorders can occur throughout the length of the gut—from the 
oesophagus to the colon. Accordingly, GI motility disorders can present with a range of chronic 
symptoms, including nausea and vomiting, that greatly affect a patient’s quality of life [1]. Difficulties 
in obtaining large amounts of human GI tissue for research have limited our understanding of GI 
motility. Currently, there are no cures for GI motility disorders, and symptom management primarily 
relies on lifestyle changes and medications. 
The GI tract is an essential system for the digestion of food, absorption of nutrients and release 
of waste. These processes occur in different segments of the GI tract, requiring the movement of 
content between segments. This movement is facilitated by active and passive peristalsis—
coordinated slow waves of muscle contraction and relaxation [2,3]. Cells responsible for GI motility 
involve smooth muscle cells, enteric neurons, and interstitial cells, including telocytes and interstitial 
cells of Cajal (ICC). A range of studies suggest that ICC act as specialised GI pacemaker cells [4,5]. 
For example, abnormalities in ICC numbers and structure have been associated with several GI 
motility disorders such as gastroparesis [6,7]. While ICC are recognised as essential for normal GI 
motility, the fundamental molecular biology of human ICC in normal or diseased GI function is yet 
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to be fully defined. As a consequence, the development of novel therapies for GI motility disorders 
has been restricted. 
In this review, we discuss the differences known between human and mouse ICC and present 
data demonstrating enrichment of human ICC-like cells from primary gastric tissue. We also examine 
gaps in the current understanding of human ICC—their sources, molecular characterisation, and 
potential involvement in GI disorders and therapy—in order to propose a framework for better 
understanding the biology of human ICC in GI motility. 
2. Anatomical Locations of ICC 
Originally described as ‘primitive neurons’ by Santiago Ramón y Cajal [8], ICC have since been 
shown to be mesenchymal-derived cells. ICC are primarily located within the muscle layer of the GI 
tract, and while they are somewhat morphologically heterogeneous [9], they are typically 
characterised by elongated cell bodies with several cell processes. Various studies have noted 
similarities between ICC and smooth muscle cells, as they share common ultrastructural features 
including caveolae and a basal lamina [10–13]. An abundance of mitochondria has also been observed 
within ICC close to the endoplasmic reticulum (ER) and plasma membrane. This led to the suggestion 
that the mitochondria form part of the pacemaker system within ICC to provide energy for regulating 
ICC membrane potential [14]. Close associations between adjacent ICC as well as with other GI cells 
also support the hypothesis that ICC may regulate GI motility. ICC interactions with neighbouring 
ICC, with smooth muscle cells (via gap junctions), and with enteric neurons (via nerve varicosities) 
have been described throughout the GI tract within mice and humans [12,15–20]. An additional gut 
cell type—previously called telocytes and now referred to as platelet-derived growth factor receptor 
alpha-positive (PDGFRα+) cells—has also been observed in close proximity to ICC (reviewed in 
[21,22]). These PDGFRα+ cells are morphologically similar to ICC and were initially referred to as 
‘ICC-like cells’. Although PDGFRα+ cells are considered to be distinct from ICC, the relationship 
between ICC and PDGFRα+ cells, as well as their role in GI motility, are yet to be fully investigated.  
2.1. ICC Subtypes 
In the 1990s, a cell surface receptor tyrosine kinase—KIT (also known as KIT proto-oncogene, c-
KIT and CD117)—was identified as an ICC marker in the GI tract [23]. This discovery was 
instrumental in enabling detailed study of ICC throughout the GI tract [24–28]. It has since been 
shown that KIT signalling (via stem cell factor; SCF) is necessary for the development and 
maintenance of mature functional ICC, and that ICC are required for the initiation of electrical activity 
in the GI tract [29–31]. However, KIT is not exclusively expressed on ICC. Other, non-ICC cell types, 
such as macrophages and mast cells, also express high levels of KIT [25,27,32]. This has led to a search 
for additional ICC markers, and more recently, anoctamin 1 (ANO1)—a calcium-activated chloride 
channel—has been validated as a more selective ICC marker in the GI tract [32]. Moreover, ANO1 
has been shown to be required for generating slow-wave activity in GI muscles [33,34]. 
ICC can also be categorised into subtypes based on their varying locations, morphology, 
functions, and cell-specific markers within the GI tract—with more molecular details understood for 
mouse ICC, as shown in Table 1 and reviewed by Komuro et al. [9,35]. For example: 
 Myenteric ICC (ICC-MY) are located surrounding the circumference of the myenteric plexus. 
They are multipolar cells with branched processes that form a network around the myenteric 
plexus. ICC-MY have been suggested to be the primary pacemaker cells of the stomach and 
small intestine muscles, involved in generating and propagating slow-wave activity through 
smooth muscle cells [4]. 
 Intramuscular ICC (ICC-IM) are found within the circular and longitudinal muscle. They are 
bipolar or spindle-shaped cells that align with the long axis of surrounding smooth muscle cells. 
ICC-IM play a key role in mediating enteric neurotransmission [36]. 
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Table 1. Key molecular characterisation studies using interstitial cells of Cajal (ICC) isolated from 
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1References are representative examples of key literature in the field and thus are not a comprehensive listing. 
 ICC of the deep myenteric plexus (ICC-DMP) are found exclusively in the small intestine. They 
are multipolar cells that are closely associated with nerve bundles of the DMP. Similar to ICC-
IM, ICC-DMP also mediate enteric neurotransmission [36]. Neurokinin-1 receptor (NK1R) has 
been used as a marker to identify and isolate murine Kit+ ICC-DMP [28]. 
 Other ICC subtypes have been described, including submucosal ICC (ICC-SM; located at the 
interface between the submucosa and circular muscle of the stomach), subserosal ICC (ICC-SS; 
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found between the serosa and longitudinal muscle of small intestine and colon) and septal ICC 
(ICC-SEP; located between and surrounding muscle bundles, particularly in larger animals like 
humans). ICC-SEP have also been implicated in propagating pacemaker activity into muscle 
bundles of the human jejunum [45]. More recently, a small stem cell-like population of ‘ICC 
progenitors’ were defined as ‘KitlowCD44+CD34+Insr+Igf1r+’ within the mouse stomach [38]. 
3. Potential Sources of ICC 
Together with their dispersed anatomical locations, the relatively small numbers of ICC within 
the gut has made investigating ICC biology highly challenging. As a result, a number of ICC sources 
have been investigated, each with its own advantages and disadvantages. 
3.1. Murine GI Tissue 
Murine GI tissues have been widely utilised as both in vitro and in vivo sources of ICC. Early 
research observed Kit+ cells within primary GI cultures, although these studies were limited as the 
cells began to lose Kit immunoreactivity and tended to trans-differentiate into a smooth muscle cell-
like phenotype [25,26]. Nonetheless, this approach has been used to demonstrate that immuno-
labelling with anti-Kit and anti-Ano1 antibodies have consistently identified ICC throughout gastric 
(stomach), small intestine and colon tissue [25,27,28,32,46]. Furthermore, several mouse models have 
been established to study ICC under normal and abnormal motility conditions. Ro et al. [39] were the 
first group to develop a transgenic model of GFP-labelled ICC (Kit+/copGFP). These mice have been 
extensively used to investigate the molecular and functional phenotypes of healthy ICC in the gut. 
Loss-of-function mutations within the Kit or Scf locus (e.g., W/Wv, Sl/Sld and W(jic)/W(jic)) have been 
used to study the absence of certain types of ICC throughout the GI muscle, showing phenotypes 
including disrupted pacemaker activity [23,47,48]. Mice with complete or conditional Ano1-
knockouts have shown loss of Ano1 immunoreactivity but continued development of Kit+ ICC 
networks, albeit with reduced slow-wave activity [33,49,50]. Mouse models of ICC in GI diseases, 
including models of diabetic gastroparesis [51] and surgical manipulations [52,53], have also been 
explored. 
3.2. Human GI Tissue 
Access to sufficient amounts of fresh normal and diseased human GI tissue for research has been 
a major challenge. Such tissue is often restricted to small amounts obtained from patient biopsies. In 
some cases, larger quantities of human GI tissue can be accessed from sleeve gastrectomy resections 
or GI cancer surgeries. Various studies have histologically identified KIT+ and ANO1+ ICC within 
gastric tissue from sleeve gastrectomy [32,54,55] and gastric cancer patients [56–58]. Similar studies 
have also been performed on small intestinal tissue from gastric bypass patients [28,32,33,59,60] and 
colon tissue from colon cancer patients [32,54,61,62]. Despite ICC appearing to display normal 
morphologies in these GI tissues, the sources of these tissues are not from healthy donors but are 
representative of a specific population (e.g., obesity or cancer). Moreover, possible variations in 
clinical characteristics among different patients have been noted. For example, Gomez-Pinilla et al. 
[54] reported that reduced numbers and collective volumes of KIT+ ICC were associated with ageing 
in both gastric and colon tissue. In other studies, similar ICC numbers were observed between obese 
and non-obese individuals [63], but increased KIT and ANO1 expression were found in gastric muscle 
biopsies of obese subjects [64]. 
3.3. Bioengineered GI Tissue 
While ICC from primary GI tissues can be harvested and cultured in vitro, loss of cell/tissue 
phenotype and function typically occurs [25,26,34,41]. Given the potential advantages of maintaining 
ICC and gut tissue in vitro for functional assessment and drug development, a number of attempts 
have been made at bioengineering GI tissue. For example, a serum-free method to culture ‘intestinal 
muscularis complexes’ using cells isolated from primary murine and human intestinal smooth 
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muscle has been described [65]. These primary cultures were maintained for up to 28 days and 
exhibited a range of gut-like properties. This included spontaneous contractions and the presence of 
gut cell types including Kit+ cells. To further maintain the functionality of ICC in vitro, STO (SIM, 
Sandos Inbred Mouse) embryonic fibroblast feeder cells have been co-cultured with enriched murine 
Kit+ ICC (purified from primary mouse intestinal smooth muscle cell mixture through the use of 
magnetic-activated cell sorting and an anti-Kit antibody) [66]. Intriguingly, this model maintained 
contractility and contained Kit+Ano1+ cells for up to 14 days. Moreover, these observations were 
replicated when enriched Kit+ ICC were replaced with the primary intestinal smooth muscle cell 
mixture (containing Kit+Ano1+ cells). While these bioengineered GI tissues represent an opportunity 
to harvest large quantities of ICC, they are complex in vitro systems involving several cell types, and 
the degree to which they mimic primary GI organs in vivo needs to be characterised in more detail. 
More recently, advancements in pluripotent stem cell technology have led to the generation of 
three-dimensional gut organoid units using a multi-stage differentiation protocol that attempts to 
recapitulate elements of embryonic GI development in vitro. The resulting human gut organoids are 
reported to be comprised of most gut cell layers, possess functions reminiscent of peristalsis, and 
display the presence of KIT+ cells [67,68]. The potential of this pluripotent stem-cell-based approach, 
while yet to be fully validated, has been extensively reviewed elsewhere [69,70]. 
4. ICC and Molecular Characteristics 
Access to large numbers of ICC is essential for advancing our molecular understanding of ICC 
biology. ICC characterisation studies have typically relied upon antibody-based purification 
methods, namely magnetic-activated cell sorting (MACS) and fluorescence-activated cell sorting 
(FACS) (reviewed in [70]). To date, FACS has proven to be the most effective approach for purifying 
Kit+ ICC from mouse GI tissue [24,27,28,37,39,40] or human GI tissue [55,61]. These isolated ICC have 
been consistently validated through real-time polymerase chain reaction (RT-PCR) analysis of genes 
considered to be ICC markers (e.g., Kit and Ano1). 
4.1. Murine ICC 
The isolation of sufficient numbers of purified murine ICC has led to fairly extensive 
characterisation via transcriptomics and functional studies (Table 1). Whole transcriptomic 
expression profiling—such as microarray and RNA-sequencing (RNA-seq)—is a powerful tool for 
investigating the molecular mechanisms that underpin cellular functions and biological processes. 
Using microarray-based transcriptomics of FACS-purified small intestinal ICC-MY and ICC-DMP, 
Chen et al. [24] were the first to show that Ano1 was a highly expressed gene in ICC. The differential 
gene expression profiles this study revealed supported the idea of different functional properties of 
ICC-MY and ICC-DMP, i.e., as pacemakers and mediators of neurotransmission, respectively. More 
recently, RNA-seq performed on populations of FACS-purified GFP+ ICC from the small intestine 
and colon of Kit+/copGFP mice demonstrated a potential new set of ICC-specific genes [40]. For example, 
Thbs4 and Hcn4 were identified as two new putative ICC markers. This same group compared their 
ICC datasets with datasets from smooth muscle cells and Pdgfrα+ cells to generate a proposed 
‘smooth muscle transcriptome browser’ [71]. However, given that each transcriptional profile arose 
from pooled cell populations obtained from 30–40 mice, the level of intra-sample heterogeneity of 
each gut cell type is not known. 
Numerous in vivo mouse studies have established a functional role for ICC as GI pacemakers 
and in GI neurotransmission as reviewed by several authors [4,5,72]. Others have investigated the 
pacemaker activity of isolated ICC, using electrophysiology and calcium imaging. Early 
electrophysiology studies demonstrated spontaneous rhythmic activity in Kit+ cells within small 
intestinal cultures, showing the activity of these cells to be similar to intact muscle [41,42]. When 
MACS-purified Kit+ cells from primary small intestinal cultures were re-cultured, electrical 
pacemaker activity was retained [25]. However, it has been noted that some pacemaker mechanisms 
may have been lost within primary ICC cultures (e.g., [34,41]). Issues relating to loss of ICC 
phenotype upon culture can, to some extent, be circumvented by analysis of freshly isolated ICC. 
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Goto et al. [43] identified large inward currents by activating depolarisation in single Kit+ cells 
isolated from the small intestine, although identification of characteristic ICC morphology amongst 
the Kit+ population (that potentially included hematopoietic cells) was challenging. More recent 
studies made use of GFP+ ICC isolated from the small intestine of Kit+/copGFP mice to more easily 
identify definitive ICC. Large inward currents were also observed in these cells, and Ano1 was 
suggested to regulate their pacemaker activity [34]. Furthermore, blocking ryanodine receptors (Ca2+ 
channels on the ER membrane) inhibited slow-wave activity [44]. Collectively, these functional 
studies on isolated ICC provide evidence that ICC pacemaker activity may be generated by 
intracellular Ca2+ release from the ER within ICC, thereby activating Ano1 channels. 
4.2. Human ICC 
In contrast to our understanding of mouse ICC, the fundamentals of human ICC biology are 
only emerging from recent studies (Table 2). This, in part, is attributed to the limited access to normal 
human GI tissue and clinical variability from surgically resected tissue. To date, only one 
transcriptional analysis of human ICC has been reported: a microarray analysis of gastric-derived, 
FACS-purified KIT+ human ICC [55]. Another study has reported morphological and histological 
analysis of FACS-purified KIT+ ICC progenitors from human colonic cancer resections [61]. Both 
studies noted the small number of isolated ICC—approximately 1000–10,000 cells per patient sample. 
Table 2. Key molecular characterisation studies using interstitial cells of Cajal (ICC) isolated from 
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1References are representative examples of key literature in the field and thus are not a comprehensive listing. 
2Note that experiments were conducted on myenteric interstitial cells of Cajal (ICC-MY) within intact tissue. 
The limited, human-specific detail we have of ICC function has ramifications for the 
development of new therapies for GI motility disorders. Electrophysiology and calcium imaging 
have shown similar pacemaker activity in ICC-MY within human small intestinal muscle strips 
compared to the mouse small intestine [59]. However, other aspects of human ICC biology do not 
appear to occur in mouse ICC. For example, immunohistochemical identification of freshly isolated 
mouse ICC has been difficult as the dissociation procedure affected the ability to visually identify 
ICC [43]. On the other hand, ICC were easier to identify in freshly dissociated human jejunum, 
whereby ICC processes were preserved [60]. KIT mRNA was also detected in individual cells visually 
identified as ICC. Additionally, the sodium channel, SCN5A, mRNA and a Na+ current were 
identified in these ICC that had electrophysiological, pharmacological, and mechano-sensitive 
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properties similar to human jejunum circular smooth muscle. This Na+ current was essentially absent 
in mouse ICC, suggesting that SCN5A activity may represent human-specific ICC biology. In a 
different study, fluorescent substance P (a ligand for NK1R) was used to histologically identify ICC-
DMP in murine and human small intestinal tissue [28]. While substance P fluorescence was 
selectively found in Kit+ ICC-DMP of murine small intestine, a similar attempt to label KIT+ ICC-DMP 
within human small intestine was found to be incomplete and non-exclusive as ICC-IM may have 
also been labelled. Taken together, these studies indicate a need to further develop and optimise 
molecular techniques specific for the investigation of human ICC biology. 
5. ICC and GI Disorders 
By defining the biology of ICC within the normal GI tract, some important links have been 
reported between ICC and GI disorders. Decreased or injured ICC have been documented in several 
human GI motility disorders, such as ageing [54], diabetic gastroparesis [63,73], Hirschsprung’s 
disease (HSCR) [74,75], and slow transit constipation [62,76,77]. However, direct translation between 
animal models and human GI physiology is yet to be fully established. A major limitation has been 
monitoring ICC loss or dysfunctions in the live human GI tract during disease development and 
progression. While animal models may be poor predictors of how novel therapies will perform in 
humans, they nevertheless have been useful in developing cellular and molecular frameworks to use 
in understanding normal biology and disease pathogenesis in humans. 
5.1. ICC and Ageing 
Alterations in GI motility have been linked to ageing, with a number of GI motility complications 
(such as constipation) occurring more frequently in the elderly population (reviewed in [78–80]). In 
one of the first studies to investigate the role of ICC in ageing, Gomez-Pinilla et al. [54] sampled 
gastric and colon tissue from patients aged 25–70 and 36–92 years old, respectively. The number and 
collective volume of KIT+ ICC networks declined by 13% per decade of life in the muscle layer of 
gastric and colon tissue. Such findings have also been demonstrated in ageing mice. In the stomach, 
jejunum and colon, Kit+ ICC numbers and networks decreased over a 24-month time period, which 
was correlated with reduced Kit protein levels [81]. Interestingly, loss of ICC was first observed in 
the stomach, followed by the intestine and colon, indicating that gastric ICC functionality may be the 
first affected during ageing. Additionally, similar changes in ICC network volumes have been found 
in the terminal bowel of ageing mice [82]. Whilst thorough molecular information regarding ICC and 
ageing is yet to be elucidated, these data indicate that a change in ICC functionality may, in part, 
affect GI motility with age. 
5.2. ICC and Diabetic Gastroparesis 
Reduced KIT+ ICC numbers have been reported in the gastric muscles of diabetic patients [56], 
which is often linked to GI motility disorders such as gastroparesis. In humans, diabetic gastroparesis 
presents as delayed gastric emptying in the absence of obstruction or any other identifiable, non-
diabetic cause [83]. Investigation of type 1 or type 2 diabetic patients has shown approximately that 
42% exhibit normal gastric emptying and 58% abnormal emptying (36% with delayed emptying and 
22% with accelerated emptying) [84]. Similar outcomes were seen in type 2 diabetic patients with 
poor glycaemic control; i.e., ~66% had abnormal (though not always symptomatic) gastric emptying 
[85]. Other studies of gastroparesis have shown ultrastructural changes in ICC and disrupted slow-
wave activity within the gastric antrum and corpus, termed ‘ICC-opathy’ (reviewed in [86]). More 
recently, some studies have suggested a link between inflammation and ICC loss in diabetic 
gastroparesis patients. Low numbers of CD206+ macrophages were found to be correlated to loss of 
KIT+ ICC within the gastric corpus of diabetic gastroparesis patients [87]. Moreover, transcriptomic 
and proteomic analyses on gastric muscle biopsies from diabetic gastroparesis patients have further 
supported this hypothesis that innate immune signalling and inflammation may play a role in disease 
pathogenesis [88,89]. 
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Delayed gastric emptying has also been observed in mouse diabetic models. Interestingly, 
reduced numbers of gastric Kit+ cells and disrupted GI pacemaker activity have been reported in type 
2 diabetic (db/db) mice [90], as well as diabetic GFP+ ICC (Kit+/copGFP; Lepob/ob) mice [39] and non-obese 
diabetic gastroparesis (NOD) mice [51]. Furthermore, a loss of Ho-1 (a cytoprotective molecule 
against oxidative stress) up-regulation was associated with decreased gastric Kit protein expression 
and delayed gastric emptying in NOD mice, suggesting a role of oxidative stress in diabetes [91]. 
Interestingly, administration of interleukin-10 (which activates the expression of Ho-1 protein) into 
NOD mice led to increased gastric emptying and more organised gastric Kit+ ICC networks [92]. In a 
different study, depleted ICC in NOD mice were also accompanied by reduced Scf production and 
smooth muscle atrophy [93]. Moreover, in organotypic gastric muscle cultures, such ICC loss was 
inhibited by insulin or Igf-1 via rescue of smooth muscle cells and Scf expression, suggesting a 
potential role of smooth muscle cells in diabetic-associated loss of ICC. On the other hand, in female 
obese type 2 diabetic leptin receptor-mutant (Leprdb/db) mice, hyperglycaemia and hyperinsulinemia 
were observed with elevated oxidative stress, rapid gastric emptying and increased gastric Kit+ ICC 
[94]. Thus, while diabetes may be associated with both ICC gain and loss, the mechanisms 
underpinning these phenomena in humans are yet to be fully explored. 
5.3. ICC and Other GI Motility Disorders 
ICC loss has also been observed along with disrupted slow-wave activity in mouse models of 
intestinal surgical resection [52] and small bowel obstruction [53]. Interestingly, after removing the 
insult, ICC networks and slow-wave activity began to recover. 
Hirschsprung’s disease (HSCR) is a congenital colon disorder that causes chronic constipation. 
Altered KIT+ ICC networks have been documented in the bowel [75] and colon [74] of HSCR patients. 
Additionally, reduced ANO1 immunoreactivity and protein levels were found in the colon of HSCR 
patients [95]. Intriguingly, in human colon samples from both normal and HSCR patients, 
KitlowCD34+Igf1r+ candidate ‘ICC progenitors’ were identified at a frequency of 0.7% of total cells [61] 
(similar to the KitlowCD34+Igf1r+ candidate ‘ICC progenitors’ identified in the mouse stomach [38]). 
Reduced proportions of mature and progenitors of ICC were reported, along with ultrastructural ICC 
injury, in the narrow part of the HSCR colon. 
5.4. ICC and Gastrointestinal Stromal Tumours (GISTs) 
Gastrointestinal Stromal Tumours (GISTs) are the most common mesenchymal tumour of the 
gut. Some 60–70% of GISTs occur in the stomach and contain activating mutations in the KIT or 
PDGFRA genes [96]. GISTs have been treated with imatinib, a tyrosine kinase inhibitor, but many 
patients eventually develop imatinib-resistance. 
One hypothesis for the development of GISTs is that they may arise from KIT+CD34+ ICC in the 
human GI tract [97,98]. However, this hypothesis is controversial as others have reported that KIT+ 
ICC are distinct from CD34+ cells [99,100]. Nonetheless, in mouse models of GIST, knock-in mutations 
in the Kit gene (K641E and KIT-Asp818Tyr) resulted in hyperplastic ICC and the development of 
GISTs, suggesting ICC may be involved in disease pathogenesis [101,102]. Lőrincz et al. [38] isolated 
KitlowCD44+CD34+Insr+Igf1r+ ‘ICC progenitors’ (representing 0.6% of the total cells) by FACS from 
mouse gastric tissue. Interestingly, these cells were able to expand with Scf and differentiate into 
mature functional ICC with Igf-1 in vitro. Transplantation of this cell population into nude mice 
showed that these ‘ICC progenitors’ induced the formation of malignant tumours containing 
Kit+Ano1+ cells [103]. Furthermore, in vitro assessment of these cells indicated they were resistant to 
imatinib as well as being resistant to neutralising antibodies against Kit and Scf—treatments that 
would normally inhibit proliferation of mature ICC. A 2016 human microarray study showed that 
genes in the hedgehog signalling pathway, molecular regulators of GI mesenchymal development, 
were altered within GIST tissue compared to FACS-purified gastric-derived ICC [55]. It was 
suggested that dysregulated hedgehog signalling—possibly within ICC—may be involved in GIST 
development. At present, these data suggest a potential role of ICC in GIST pathogenesis. In 
Int. J. Mol. Sci. 2020, 21, 4540 9 of 18 
 
particular, the mouse data suggests that ‘ICC progenitors’ may be GIST precursors and potential 
targets for GIST therapy. 
6. ICC and GI Therapy 
It is clear from numerous studies that loss of normal ICC functioning is implicated in a range of 
GI-related diseases. Despite this, the specific role of ICC in disease pathology is still poorly 
understood—indicating more detailed molecular characterisation of normal and diseased ICC at 
different stages of disease is required. Such increased knowledge of ICC biology could identify novel 
drug targets and candidate small molecules to restore impaired ICC function. Towards this end, some 
initial steps have been made towards regeneration of rudimentary ICC networks and restoration of 
pacemaker functions, particularly with murine ICC. 
6.1. Cell-based ICC Therapy 
Mouse stem-cell-like ‘ICC progenitors’—isolated from gastric tissue by FACS—have been 
shown to regenerate and maintain mature ICC networks under certain conditions in vitro [38]. 
However, as such a cell population is rare, further research is required to identify and characterise 
these cells in the human GI tract. Nevertheless, these ‘ICC progenitors’, and other possible stem-cell-
derived ICC [69,70], may represent a promising route to investigate potential regenerative therapies 
as well as personalised medicine for GI disorders. 
Several groups have investigated ICC transplantation as an alternative approach. One of the first 
attempts involved allotransplantation of isolated ICC from Kit+/copGFP mice into small intestinal muscle 
strips of W/Wv mutant mice [104]. This resulted in development of Kit+ ICC-MY networks along with 
functional pacemaker activity. Other groups have used both a different potential source of ICC 
progenitors and a different method of transplantation. Bone-marrow-derived mesenchymal stem 
cells have been shown to recolonise injured organs including the intestinal epithelium [105,106]. 
Interestingly, transplanted mouse GFP+ bone marrow-derived cells were able to migrate into the GI 
tract, where they appeared to differentiate into Kit+ ICC-like cells within the myenteric plexus of the 
small intestine following intestinal injury [107]. Similar findings were also reported along with 
improved gastric emptying in W/Wv mutant mice [108]. However, McCann et al. [109] found that 
when GFP+Kit+ bone-marrow-derived cells (from Kit+/copGFP mice) were transplanted into the small 
intestine of W/Wv mutant mice, they did not observe these cells differentiate into network-forming 
ICC-like cells. These contradictory findings indicate more detailed molecular and functional 
characterisation of the transplanted cells is needed before the potential utility of this approach can be 
properly assessed. 
6.2. Scaffold-Based ICC Therapy 
As ICC are a mesenchymal-derived cell type, a 2018 study seeded mouse mesenchymal stem 
cells onto a hydrogel scaffold and then placed it onto the luminal side of gastric explants in vitro 
[110]. Some of the mesenchymal stem cells appeared to successfully migrate into the gastric tissue, as 
evidenced by Kit+ staining. However, typical ICC networks were not seen to develop. When primary 
cultured mouse ‘intestinal muscularis complexes’ (containing Kit+ cells) were combined with 
electrospun poly-caprolactone scaffold sheets in vitro, spontaneous contractions were observed [65]. 
Similar findings occurred when electrospun poly-caprolactone scaffold sheets were seeded with STO 
feeder cells and primary MACS-purified mouse Kit+ ICC [66], thus demonstrating attachment and 
alignment onto the scaffold sheets in vitro. In addition, when a primary mouse intestinal smooth 
muscle cell mixture was cultured on STO-seeded electrospun poly-caprolactone scaffold sheets, 
rhythmic contractions developed, and Kit+Ano1+ cells were observed after 10 weeks. While this 
approach may represent a more clinically relevant approach, improved in vitro ICC maintenance 
conditions for scaffolds may need to be established prior to assessment in animal transplantation 
studies. 
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7. Establishing a Source of Candidate Human ICC for Molecular Characterisation 
As a step towards obtaining a large source of human ICC, we have used immunofluorescence 
and flow cytometry to search for ICC in gastric tissue derived from human sleeve gastrectomy 
patients (Figure 1A). Immunofluorescence showed KIT+/ANO1+ cells present within the gastric 
muscle layer (Figure 1B–E), consistent with previous reports of ICC in human gastric tissue [32,58]. 
Dissociation of the gastric muscle tissue into single-cell suspensions enabled capture of KIT+/CD45-
/CD11b- cells via flow cytometry (Figure 1F,G), similar to published analysis of gastric-derived FACS-
purified human ICC [55]. On average, these candidate ICC represented ~0.8% of the total sorted live 
cell count, with ~2700 ICC obtained per sample (Figure 1G). Encouragingly, these KIT+/CD45-/CD11b- 
candidate ICC were significantly enriched (11-fold) in ANO1 mRNA expression. They also had 
retained KIT mRNA expression and had reduced (to 0.1-fold) mRNA expression of both the 
hematopoietic markers CPA3 and CD68 (Figure 1H). 
 
Figure 1. Identification and capture of candidate interstitial cells of Cajal (ICC) from human gastric 
muscle tissue. (A) Outline of the experimental workflow for processing human sleeve gastrectomy 
samples for immunofluorescence or flow cytometry. (B–E) Immunofluorescence data obtained from 
cryosections of human gastric muscle stained with DAPI nuclear stain (blue) and antibodies that 
detect ICC marker proteins ANO1 (B; green) and KIT (C; red), with overlapping expression observed 
(D; ANO1+KIT+DAPI). A representative negative control (E; secondary antibody only control+DAPI) 
shows no background staining, thereby supporting the specificity of the staining patterns seen in B-
D. Images were taken at 40× objective on the Zeiss Axio Imager M2 microscope. Scale bar = 50 μm. (F) 
A representative fluorescence-activated cell sorting (FACS) plot illustrating key human sleeve 
gastrectomy cell populations including: KIT+/CD45-/CD11b- ICC (red box); hematopoietic cells (HP; 
KIT-/CD45+/CD11b+) (grey box); and mast cells (MC; KIT+/CD45+/CD11b+) (grey box). (G) Plot of ICC 
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frequency and total sorted ICC numbers. Each dot represents an individual patient sample. (H) RT-
PCR verification of cell marker genes in the FACS-captured ICC population: ANO1 (ICC), KIT (ICC, 
mast cells), CPA3 (mast cells), and CD68 (hematopoietic cells). Data were normalised against GAPDH 
mRNA levels, expressed relative to unsorted cells (dotted line), and represented as mean fold change 
± standard error of the mean from three biological samples. Data were analysed using paired t-test; * 
p < 0.05, ** p < 0.01. 
Based on these initial findings, primary human gastric ICC can be obtained in sufficiently high 
numbers for molecular characterisation via immunofluorescence, transcriptomics, and proteomics, 
and also functional analyses such as electrophysiology and calcium imaging (Figure 2). Such 
fundamental characterisation will assist in identifying the transcriptional networks, and also growth 
factors and signalling pathways, that are important for controlling human ICC biology. In turn, these 
future studies will help to identify new drug targets (e.g., ion channels) and related candidate drugs 
relevant to ICC-associated GI disorders. Molecular characterisation of primary human gastric ICC 
will also provide other useful information, such as identification of transcription factors responsible 
for maintaining a human ICC subtype. This information could then be used to generate a much larger 
source of human ICC. For example, through optimisation of human stem-cell-differentiation 
strategies [67–70], or through trans-differentiation mediated by over-expression of ICC-expressed 
transcription factors [111]. A sustainable source of human ICC will help to i) define the molecular 
pathology of GI disorders using human cells rather than animal models and ii) facilitate development 
of ICC transplantation strategies (with or without cell scaffolds) for GI disorders. 
 
Figure 2. Workflow for characterisation of patient-derived human gastric interstitial cells of Cajal 
(ICC). 
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8. Conclusions and Future Prospects 
Current treatments for GI motility disorders are limited and inadequate. This leads to chronic 
and debilitating GI symptoms that cause long-term reductions in the quality of life for millions of 
patients worldwide. While ICC are recognised as necessary for normal GI motility, they also exhibit 
key pathologies within several GI diseases. Encouragingly, ICC also show potential for regenerative 
medicine and present an important cellular target for therapy. 
Over the last few decades, an extensive body of work has established some fundamental 
molecular characteristics of murine ICC in both normal and diseased GI tissue. However, it is unclear 
how closely these findings can be translated to human GI physiology and disease treatment. The 
scarcity of large sources of normal and diseased human GI tissues for molecular analysis has greatly 
limited our fundamental understanding of human ICC and their involvement in GI-related diseases. 
Here, we show that human gastric tissue is an appropriate source of FACS-purified primary human 
ICC. Future research that focuses on further characterising these primary human ICC will help define 
mechanistic details of their role in human GI biology. In turn, this will assist in developing potential 
cell- or drug-based therapies to treat GI disorders. 
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